


New pharma legislation

Implementation & Stakeholder engagement


Joint PCWP/HCPWP meeting, 04.02.2026




Key elements of the new pharma legislation (NPL)



Proposed NPL governance structure



Delivery streams requiring patient and HCP input



Engaging patients and HCP representatives during NPL implementation



Multi-stakeholder workshop

What: High-level workshop with all stakeholder groups (EMA, EC, NCAs, industry, patients, HCPs).

When: Organised as soon as practicable after the publication of the final legislative text in the Official Journal.

Purpose: Provide an overview of the foreseen changes and gather early reflections to guide implementation planning.



PCWP & HCPWP

What: Main reference forum for patients and healthcare professionals during NPL implementation.

When: In line with the regular PCWP/HCPWP meeting cycle (topics brought as needed).

Purpose: Share overarching progress and upcoming milestones, clarify questions, gather high-level input, and keep alignment with patient/HCP representatives as implementation evolves.




Topic-specific consultations

What: Targeted consultations with patients and/or HCP representatives for specific implementation topics.


When: On a needed basis, triggered by concrete implementation questions and timelines.

Purpose: Work through practical implications, validate approaches, and collect operational input to inform implementation deliverables (e.g., guidance, communications, user needs, roll-out plans).

Keeping stakeholders informed and involved throughout implementation



New EMA NPL web page: just published!



[Reform of the EU pharmaceutical legislation](#)
[| European Medicines Agency \(EMA\) webpage](#)



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

Thank you

Follow us

